INBX — Inhibrx Biosciences Inc. stock price, charts and financials

Latest market price

93.11

+4.45+5.02%

Overview Short InterestFilings

INBXQT73Inhibrx Biosciences Inc.·NASDAQ

Overview Short InterestFilings

93.11+5.02%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.52%$15.45 MESO+4.64%$16.68 ZBIO-1.48%$31.95 GHRS-2.44%$29.53 TSHA-2.90%$6.37 STOK-1.47%$32.23 ABCL+34.78%$9.34 VRDN-2.25%$23.06

Snapshot

Index	-	P/E	-	EPS (ttm)	-2.92	Insider Own	-	Shs Outstand	14.67M	Perf Week	8.06%

Market Cap	1.30B	Forward P/E	-	EPS next Y	-6.53	Insider Trans	0.00%	Shs Float	10.87M	Perf Month	-14.63%

Enterprise Value	1.14B	PEG	0.09	EPS next Q	-	Inst Own	-	Short Float	31.60%	Perf Quarter	-28.80%

Income	-122.53M	P/S	-	EPS this Y	-216.27%	Inst Trans	-	Short Ratio	7.35	Perf Half Y	8.75%

Sales	1.30M	P/B	-	EPS next Y	29.29%	ROA	-70.77%	Short Interest	3.43M	Perf YTD	12.23%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-563.89%	52W High	163.09 -42.91%	Perf Year	322.59%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-76.97%	52W Low	21.58 331.44%	Perf 3Y	-

Dividend Est.	0.85 (0.91%)	EV/EBITDA	-	Sales past 3/5Y	-20.63% -40.13%	Gross Margin	-80.38%	Volatility	5.11% 5.72%	Perf 5Y	-

Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-102.50%	Oper. Margin	-9465.46%	ATR (14)	5.47	Perf 10Y	-

Dividend Ex-Date	May 30, 2024	Quick Ratio	6.46	Sales Y/Y TTM	-	Profit Margin	-10014.23%	RSI (14)	51.86	Recom	2.40

Dividend Gr. 3/5Y	-	Current Ratio	6.46	EPS Q/Q	23.21%	SMA20	3.70%	Beta	2.51	Target Price	325.00

Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	-2.74%	Rel Volume	1.15	Prev Close	88.66

Employees	110	LT Debt/Eq	13.13	Earnings	Aug 12	SMA200	4.30%	Avg Volume	356.06K	Price	93.11

IPO Date	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-28.36% -	Net Debt/EBITDA	1.34	Volume	407,679	Change	5.02%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-15-26	Reiterated	Stifel Nicolaus		$300 → $325
Jan-23-24	Downgrade	JMP Securities	Market Outperform → Market Perform

Latest News

Jul-25-26

Jul-25-2609:36AM

Inhibrx Biosciences: The Whole Story Rides On INBRX-106SeekingAlpha

Jul-17-26

Jul-17-2606:43AM

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening ActSeekingAlpha

Jul-16-26

Jul-16-2609:00AM

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Millionprnewswire.com

Jul-09-26

Jul-09-2601:01PM

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choicezacks.com

Jun-15-26

Jun-15-2601:15PM

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional ChondrosarcomaYahoo

09:19AM

Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027Benzinga

Company

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	8	1	0	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	33	2	2	—	—	—	—	—	—
Gross Profit	-22	-1	-2	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	17	23	128	—	—	—	—	—	—
Research and Development	92	113	204	—	—	—	—	—	—
Other Operating Expense	-1	-2	-3	—	—	—	—	—	—
Operating Income	-102	-135	-331	—	—	—	—	—	—
Interest Expense	9	12	13	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	0	7	2,033	—	—	—	—	—	—
Net Income Before Taxes	-111	-140	1,688	—	—	—	—	—	—
Income Taxes	2	0	0	—	—	—	—	—	—
Consolidated Net Income	-113	-140	1,688	—	—	—	—	—	—
Net Income From Continuing Operations	-113	-140	1,688	—	—	—	—	—	—
Net Income	-113	-140	1,688	—	—	—	—	—	—
EPS (Recurring)	-2.92	-9.04	116.58	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.92	-9.04	116.58	—	—	—	—	—	—
EPS (Diluted)	-2.92	-9.04	116.58	—	—	—	—	—	—
EBITDA	-101	-125	1,703	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	0.13	—	—	—	—	—	—
Price To Sales Ratio	453.91	1,185.00	—	—	—	—	—	—	—
Gross Margin	-275.00	-100.00	—	—	—	—	—	—	—
Operating Margin	-1,275.00	-13,500.00	—	—	—	—	—	—	—
Net Margin	-1,412.50	-14,000.00	—	—	—	—	—	—	—
Shares Outstanding	39	15	14	—	—	—	—	—	—
Market Capitalization	3,631	1,185	216	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIKING GLOBAL INVESTORS LP	10% Owner	Oct 07 '25	Sale	32.25	350,000	11,287,501	67,018	Oct 09
Kayyem Jon Faiz	Director	Nov 20 '24	Buy	14.19	18,750	266,102	69,843	Nov 22
Kayyem Jon Faiz	Director	Nov 19 '24	Buy	14.23	34,843	495,708	51,093	Nov 22
Vuori Kristiina MD	Director	Oct 03 '24	Buy	15.00	6,667	100,005	20,443	Oct 07
Lappe Mark	Chief Executive Officer	Sep 16 '24	Buy	17.13	13,037	223,324	705,548	Sep 16
Lappe Mark	Chief Executive Officer	Sep 12 '24	Buy	15.05	26,963	405,793	692,511	Sep 16
Vuori Kristiina MD	Director	Sep 11 '24	Buy	15.07	6,457	97,307	13,776	Sep 12
Vuori Kristiina MD	Director	Sep 10 '24	Buy	15.00	179	2,685	7,319	Sep 12
Lappe Mark	Chief Executive Officer	Sep 10 '24	Buy	15.19	8,500	129,115	665,548	Sep 10
Lappe Mark	Chief Executive Officer	Sep 09 '24	Buy	15.21	9,500	144,495	657,048	Sep 10
Lappe Mark	Chief Executive Officer	Sep 06 '24	Buy	15.29	26,000	397,540	647,548	Sep 10
MANHARD KIMBERLY	Director	Aug 28 '24	Buy	13.98	10,000	139,800	10,000	Aug 30
FORSYTH DOUGLAS	Director	Aug 23 '24	Buy	14.07	59,812	841,555	224,564	Aug 26
FORSYTH DOUGLAS	Director	Aug 22 '24	Buy	12.89	15,188	195,773	164,752	Aug 26
Lappe Mark	Chief Executive Officer	Aug 21 '24	Buy	12.93	12,945	167,379	54,865	Aug 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.